Pixium Vision, a Paris, France-based developer of innovative retinal implant systems, closed a €15m Series A extension financing.
The round was led by Sofinnova Partners, with participation from Bpifrance, through the InnoBio fund, and existing investors Omnes Capital and Abingworth. In conjunction with the financing, Antoine Papiernik (Sofinnova Partners) and Chahra Louafi (Bpifrance) joined Pixium’s board of directors.
The company intends to use the funds to advance the development of its IRIS retinal implant systems.
Co-founded by Dr Bernard Gilly and Prof. José-Alain Sahel in November 2011, Pixium is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. Its first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development.
In addition, the company is developing a sub-retinal implant system (IRIS3), which has the potential to improve vision significantly compared to IRIS1 and IRIS2.